|
Dalpicilib-Enhanced vs. Standard Endocrine Therapy in ER+ HER2- Early Breast Cancer
RECRUITINGPhase 3Sponsored by Fudan University
Actively Recruiting
PhasePhase 3
SponsorFudan University
Started2025-01-09
Est. completion2030-09-30
Eligibility
Age18 Years – 70 Years
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT06637150
Summary
This study aims to conduct a randomized controlled clinical trial to compare the efficacy and safety of dalpicilib combined with endocrine therapy versus standard endocrine therapy in ER-positive, HER2-negative, lymph node-negative patients with risk factors, in order to further optimize the regimen for adjuvant endocrine therapy in breast cancer.
Eligibility
Age: 18 Years – 70 YearsSex: FEMALEHealthy volunteers accepted
Inclusion Criteria: 1. Women aged 18-70 years 2. ECOG score of 0-1 3. Histologically confirmed unilateral invasive cancer (regardless of pathology type) 4. No macroscopic or microscopic tumor residue after surgical resection 5. Early-stage breast cancer, pathologically confirmed as ER-positive and HER2-negative (ER-positive defined as immunohistochemical detection of ER \>10% of tumor cells positive; HER2 0-1+ or HER2 2+ but FISH negative, with no amplification, defined as HER2-negative) 6. Postoperative pathological staging of pT1c or above, N0M0, and meeting one of the following criteria: (1) G3; (2) G2 and meeting one of the following: i. Ki-67 ≥20%; ii. 21-gene recurrence score ≥26 or high genomic risk profile; iii. Age ≤40 years and vascular invasion positive 7. No prior neoadjuvant treatment 8. Time from surgery or completion of chemotherapy or radiotherapy (whichever occurs later) to randomization does not exceed 8 weeks 9. Good postoperative recovery, at least 1 week after surgery 10. Normal function of major organs, meeting the following criteria: (1) Hematological criteria: HB ≥90 g/L (no blood transfusion in the last 14 days); ANC ≥1.5 × 10\^9 /L; PLT ≥100 × 10\^9 /L; (2) Biochemical criteria: TBIL ≤1.5 × ULN (upper limit of normal); ALT and AST ≤3 × ULN; serum Cr ≤1.5 × ULN 11. Women of childbearing age must use contraception during treatment 12. Subjects voluntarily join this study, sign informed consent, demonstrate good compliance, and cooperate with follow-up Exclusion Criteria: 1. Bilateral breast cancer or ductal/lobular carcinoma in situ (DCIS/LCIS) 2. Received treatment for advanced disease 3. Metastasis at any site 4. Any tumor \> T4a (with skin involvement, fixation, inflammatory breast cancer) 5. Clinically or radiologically suspected malignancy in the contralateral breast not confirmed and requiring biopsy 6. Received neoadjuvant therapy, including chemotherapy, radiotherapy, and endocrine therapy 7. History of malignant tumors within the past 5 years (excluding basal cell carcinoma of the skin and cervical carcinoma in situ), including contralateral breast cancer 8. Patient has been enrolled in other clinical trials 9. Patient has severe systemic diseases and/or uncontrolled infections that prevent participation in the study 10. Severe cardiovascular or cerebrovascular diseases within 6 months prior to randomization (e.g., unstable angina, chronic heart failure, uncontrolled hypertension \>150/90 mmHg, myocardial infarction, or stroke) 11. Known allergy to relevant medications 12. Women of childbearing age who refuse contraception during treatment and for 8 weeks after treatment completion 13. Pregnant or breastfeeding women 14. Positive pregnancy test before drug administration after joining the trial 15. Individuals with mental illness or cognitive impairment who cannot understand the trial protocol and its side effects, unable to comply with the protocol and follow-up (systematic assessment required prior to enrollment) 16. Individuals without personal freedom and independent civil capacity
Conditions2
Breast CancerCancer
Interventions2
Related trials
- Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer — Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Current Status of Treatment for Chinese Patients With ESR1-mutated HR+/HER2-advanced Breast Cancer — SciClone Pharmaceuticals
- Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer — The First Affiliated Hospital with Nanjing Medical University
- Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure — Tianjin Medical University Cancer Institute and Hospital
- Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients — Region Örebro County
- Negative/Low Hormone Receptor And/or HER2 POsitive Lobular Invasive Breast Carcinoma - A Real-World International Cohort Study — Istituto Oncologico Veneto IRCCS
- Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer — GBG Forschungs GmbH
- Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer — Xijing Hospital
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 3
SponsorFudan University
Started2025-01-09
Est. completion2030-09-30
Eligibility
Age18 Years – 70 Years
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT06637150